Galway Medical Tech Company Aerogen to Expand with 700 New Jobs

The medical technology landscape in galway is thriving, with Aerogen, a trailblazer in aerosol drug delivery, spearheading a monumental expansion. This enterprising move is set to create over 700 new jobs, a testament to Ireland’s burgeoning economic prowess.

From its inception in Maigh cuilinn in 1998, aerogen has evolved into a global powerhouse, employing hundreds across 28 countries. Its innovative devices are revolutionizing medication delivery for patients worldwide. The company’s latest €300 million investment plan underscores its commitment to further innovation and growth.

The expansion will primarily focus on developing new products and venturing into the biopharmaceutical sector, generating 725 jobs in Galway and Shannon by 2035. This aligns seamlessly with Enterprise Ireland’s annual report, which highlights unprecedented employment levels among its client companies.

According to the report, 2024 saw a net increase of 6,200 jobs, with overall employment levels rising by 3% compared to 2023. Currently, over 234,000 people are employed by these firms, with two-thirds of these jobs located outside the capital. the export value generated by these companies stands at a staggering €30 billion annually.

Leo Clancy, CEO of Enterprise Ireland, emphasized the agency’s pivotal role in fostering economic growth. He noted that employment surged across three core sectors in 2024: technology and services,industrial and life sciences,and food and sustainability. While 15,741 jobs were created last year, offsetting losses at some companies resulted in a net increase of 6,212 positions.

“These results provide a strong platform on which to further expand the country’s enterprise potential in the coming years,” Mr. Clancy said. The success of companies like Aerogen highlights the vital role of Irish-owned, globally focused businesses in driving the nation’s economic momentum.

Beyond aerosol drug delivery, what other avenues of medical technology innovation is Aerogen exploring for its expansion into the biopharmaceutical sector?

Aerogen’s Ambitious Expansion: Boosting Ireland’s Medical Tech Landscape

An Exclusive Chat with Dr. fiona Brennan, Chief Innovation Officer at Aerogen

Ireland’s medical technology sector is witnessing a transformative moment as Aerogen, a pioneer in aerosol drug delivery, unveils a €300 million expansion plan. This bold move is set to create 725 new jobs in Galway and Shannon by 2035, solidifying the company’s role as a global leader. We spoke with Dr. Fiona Brennan, Aerogen’s Chief Innovation officer, to delve into the details of this expansion, its implications for healthcare, and its contribution to Ireland’s economic growth.

Aerogen’s Growth and Its Regional Impact

Q: Aerogen’s expansion is a major advancement for both the company and Ireland. What does this mean for Aerogen and the regions of Galway and shannon?

Dr. Fiona Brennan: “this expansion represents a notable milestone for us. From our modest start in Maigh Cuilinn in 1998, we’ve grown into a global presence, operating in 28 countries. This investment will allow us to innovate further, particularly in the biopharmaceutical sector, which is evolving rapidly. The creation of 725 jobs in galway and Shannon reflects our commitment to fostering local economic growth while maintaining our position as a leader in medical technology innovation.”

Revolutionizing Healthcare Through Innovation

Q: Aerogen’s devices are reshaping how patients receive treatments. How do you envision this technology influencing the future of healthcare?

Dr.Fiona Brennan: “Our mission has always been to simplify medication delivery for patients.By focusing on aerosol drug delivery, we’re making treatments more accessible and efficient, especially for those managing chronic conditions. This expansion will allow us to push boundaries further—imagine patients self-administering complex medications with ease. It’s about empowering individuals and reducing barriers to care.”

Aerogen and Ireland’s Thriving Economy

Q: enterprise Ireland’s recent report highlighted record employment levels, with a net increase of 6,200 jobs in 2024. How does Aerogen contribute to this success?

Dr. Fiona Brennan: “Aerogen’s achievements are a testament to the supportive ecosystem Enterprise Ireland has cultivated. Their emphasis on technology, industrial and life sciences, and food sustainability aligns seamlessly with our objectives. As we continue to grow, we’re proud to play a part in Ireland’s economic progress while advancing medical technology on a global scale.”

Aerogen’s expansion is not just a win for the company but a significant boost for Ireland’s medical tech industry and economy. With its focus on innovation and patient-centric solutions, Aerogen is poised to remain a key player in shaping the future of healthcare.

The Power of Irish Innovation: Driving Global Economic Growth

Ireland has always been a hub of innovation, and its businesses are making a significant impact on the global stage. With an annual export value of €30 billion,Irish companies are not just contributing to their local economy—they are shaping the future of industries worldwide. This remarkable achievement highlights the potential of Irish innovation and its ability to compete on an international scale.

A Thought-Provoking Question for Readers

Q: With Aerogen venturing into biopharmaceuticals, how do you think this sector will evolve in the next decade?

Dr. Fiona Brennan: “The biopharmaceutical sector is poised for tremendous growth, as it bridges the gap between biology and medicine. I envision personalized treatments becoming mainstream, with companies like Aerogen leading this transformative shift. But I’d like to hear from readers—what innovations in biopharmaceuticals do you think will revolutionize healthcare?”

To share your thoughts, leave a comment below.

What are the new areas of medical technology innovation that Aerogen is exploring as part of its expansion into the biopharmaceutical sector?

Aerogen’s Aspiring Expansion: Boosting Ireland’s Medical Tech Landscape

An Exclusive Chat with Dr. Fiona Brennan, Chief Innovation Officer at Aerogen

Ireland’s medical technology sector is witnessing a transformative moment as Aerogen, a pioneer in aerosol drug delivery, unveils a €300 million expansion plan. This bold move is set to create 725 new jobs in Galway and Shannon by 2035, solidifying the company’s role as a global leader. We spoke with Dr. Fiona Brennan, Aerogen’s Chief Innovation Officer, to delve into the details of this expansion, its implications for healthcare, and its contribution to Ireland’s economic growth.

aerogen’s Growth and Its Regional Impact

Q: Aerogen’s expansion is a major advancement for both the company and Ireland. What does this mean for Aerogen and the regions of Galway and Shannon?

Dr. Fiona Brennan: “This expansion represents a notable milestone for us. From our modest start in Maigh Cuilinn in 1998, we’ve grown into a global presence, operating in 28 countries. this investment will allow us to innovate further,particularly in the biopharmaceutical sector,which is evolving rapidly. The creation of 725 new jobs in galway and Shannon is not just a testament to our growth but also a significant boost to the local economy. These regions will benefit from increased employment opportunities, enhanced infrastructure, and a stronger presence in the global medical tech industry.”

Beyond Aerosol Drug Delivery: Exploring New Avenues in Biopharmaceutical Innovation

Q: Beyond aerosol drug delivery, what other avenues of medical technology innovation is Aerogen exploring for its expansion into the biopharmaceutical sector?

Dr. Fiona Brennan: “While aerosol drug delivery remains a cornerstone of our business, we are actively exploring several new avenues to diversify and deepen our impact in the biopharmaceutical sector. One key area is the development of advanced drug delivery systems that utilize nanotechnology to enhance precision and efficacy. we are also investing in the creation of personalized medicine solutions, leveraging genetic data to tailor treatments for individual patients. Additionally, we are exploring the integration of artificial intelligence in our devices to optimize drug delivery and monitor patient response in real-time. These innovations not only expand our capabilities but also align with the global trend towards more personalized and efficient healthcare solutions.”

Fostering Innovation and Collaboration

Q: How does Aerogen plan to foster innovation and collaborate with other players in the biopharmaceutical sector?

Dr.Fiona Brennan: “Innovation is at the heart of Aerogen’s strategy, and we are committed to fostering a culture of continuous improvement. We are establishing partnerships with leading research institutions and universities to drive cutting-edge research. Collaboration with other biopharmaceutical companies is also a priority, as we believe that shared knowledge and resources can accelerate advancements. Our expansion includes the creation of state-of-the-art research facilities in Galway and Shannon, which will serve as hubs for innovation and collaboration. These facilities will not only support our internal R&D efforts but also provide a platform for external partners to work alongside us in pushing the boundaries of medical technology.”

On Aerogen’s Expansion and Job Creation

Q: Aerogen’s expansion is set to create 725 new jobs by 2035. What roles will these encompass, and how will Aerogen support the development of its workforce?

Dr. Fiona Brennan: “The new jobs will span a wide range of roles, from research and development to manufacturing, marketing, and support services. We are particularly focused on creating opportunities for skilled professionals in science, engineering, and technology, as these are the backbone of our innovation efforts. To support our workforce, we are investing in comprehensive training programs, partnerships with educational institutions, and a robust mentorship system. Our goal is not just to create jobs but to nurture talent that can drive the future of medical technology both at Aerogen and globally. Additionally, we are committed to fostering diversity and inclusion in our workforce, ensuring that our growth benefits a broad spectrum of individuals and communities.”

The Role of Aerogen in Ireland’s Economic Momentum

Q: What role does Aerogen’s expansion play in Ireland’s broader economic momentum, particularly in the context of Enterprise Ireland’s recent report highlighting job growth?

Dr. Fiona Brennan: “Aerogen’s expansion is a testament to Ireland’s thriving enterprise ecosystem, as highlighted in Enterprise Ireland’s report. Our investment and job creation contribute directly to the net increase of employment in the country, particularly in the life sciences sector. The export value generated by our innovative products aligns with the €30 billion annual export figure mentioned in the report. By strengthening Ireland’s presence in the global medical tech market, we are not only driving economic growth but also positioning Ireland as a hub for innovation in healthcare. The success of companies like Aerogen underscores the importance of Irish-owned, globally focused businesses in sustaining and accelerating the nation’s economic momentum.”

Conclusion

Aerogen’s ambitious expansion plan represents a significant leap for both the company and Ireland’s medical technology sector. With a €300 million investment, the creation of 725 new jobs, and a focus on groundbreaking innovations, Aerogen is poised to solidify its role as a global leader in medical technology. As Dr. Fiona Brennan emphasized,this expansion is not just about growing the company but also about driving Ireland’s economic momentum and advancing healthcare solutions for patients worldwide. Aerogen’s journey from its humble beginnings in Maigh cuilinn to its global presence today is a testament to the transformative power of innovation and enterprise in shaping the future of medical technology.